viewHemoGenyx Pharmaceuticals

Hemogenyx reports encouraging data for bone marrow transplant therapy

"This new data demonstrates our continuing progress in developing potential uses for our CDX antibody.”

CDX antibody helps the body target cancerous cells

HemoGenyx Pharmaceuticals PLC (LON:HEMO) found good gains on Wednesday after it said pre-clinical trials in animals indicate its CDX antibody is effective as a conditioning therapy in bone marrow transplants.

Conditioning is a pre-requisite for a transplant but it is extremely toxic and has severe side effects, which reduces the number of people eligible.

READ: Hemogenyx soars as CDX antibody demonstrates effectiveness against acute myeloid leukemia

In vivo data showed CDX helps the human body’s own defences (T-cells) to target the cancerous cells.

Vladislav Sandler, Hemogenyx’s chief executive, said he was ‘much encouraged by this new data’.

"This new data demonstrates our continuing progress in developing potential uses for our CDX antibody.”

Today’s results are the latest in a string of promising updates about CDX from Hemogenyx.

Over the past two weeks, lab test results showed the antibody was effective against two types of blood cancer: acute myeloid leukemia and acute lymphoblastic leukemia, where transplants are the standard treatment.

In afternoon trading, shares in Hemogenyx were 7.7% higher at 2.80p.

 -- Adds share price --

Quick facts: HemoGenyx Pharmaceuticals

Price: 6.56666 GBX

Market: LSE
Market Cap: £28.48 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...



HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read